1) | Matsuda A, Matsuda T, Shibata A, Katanoda K, Sobue T, Nishimoto H and The Japan Cancer Surveillance Research Group. Cancer Incidence and Incidence Rates in Japan in 2007: A Study of 21 Population-based Cancer Registries for the Monitoring of Cancer Incidence in Japan (MCIJ) Project. Japanese Journal of Clinical Oncology, 2013;43(3):328-336. |
2) | Long HJ 3rd. Management of metastatic cervical cancer: review of the literature. J Clin Oncol. 2007;25:2966-2974. |
3) | Mabuchi S, Isohashi F, Yoshioka Y, Temma K, Takeda T, Yamamoto T, Enomoto T, Morishige K, Inoue T, Kimura T. Prognostic factors for survival in patients with recurrent cervical cancer previously treated with radiotherapy. Int J Gynecol Cancer. 2010 Jul;20(5):834-40. |
4) | Guckenberger M, Bachmann J, Wulf J, Mueller G, Krieger T, Baier K, Richter A, Wilbert J, Flentje M. Stereotactic body radiotherapy for local boost irradiation in unfavourable locally recurrent gynaecological cancer. Radiother Oncol. 2010 Jan;94(1):53-9. |
5) | Bazhenov AG, Guse?nov KD, Khadzhimba AV, Baranov SB, Il’iashenko SA, Maksimov SIa. Results of treatment for recurrent cancer of the uterine cervix. Vopr Onkol. 2009;55(3):319-26 abstract. |
6) | Smaniotto D, D’Agostino G, Luzi S, Valentini V, Macchia G, Mantini G, Margariti PA, Ferrandina G, Scambia G. Concurrent 5-fluorouracil, mitomycin C and radiation with or without brachytherapy in recurrent cervical cancer: a scoring system to predict clinical response and outcome. Tumori. 2005 Jul-Aug;91(4):295-301. |
7) | Moore DH, Blessing JA, McQuellon RP, Thaler HT, Cella D, Benda J, Miller DS, Olt G, King S, Boggess JF, Rocereto TF. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix:a gynecologic oncology group study. J Clin Oncol. 2004 Aug 1;22(15):3113-9. |
8) | Pérez-Regadera J, Sánchez-Muñoz A, De-la-Cruz J, Ballestín C, Lora D, García-Martín R, Sotoca A, Pérez-Ruiz E, Lanzós E. Impact of epidermal growth factor receptor expression on disease-free survival and rate of pelvic relapse in patients with advanced cancer of the cervix treated with chemoradiotherapy. Am J Clin Oncol. 2011 Aug;34(4):395-400. |
9) | Koh WJ, Greer BE, Abu-Rustum NR, Apte SM, Campos SM, Chan J, Cho KR, Cohn D, Crispens MA, DuPont N, Eifel PJ, Gaffney DK, Giuntoli RL 2nd, Han E, Huh WK, Lurain JR 3rd, Martin L, Morgan MA, Mutch D, Remmenga SW, Reynolds RK, Small W Jr, Teng N, Tillmanns T, Valea FA, McMillian NR, Hughes M. Cervical cancer. J Natl Compr Canc Netw. 2013 Mar 1;11(3):320-43. |
10) | Rutledge S, Carey MS, Prichard H, Allen HH, Kocha W, Kirk ME. Conservative surgery for recurrent or persistent carcinoma of the cervix following irradiation:is exenteration always necessary ? Gynecol Oncol. 1994 Mar;52(3):353-9. |
11) | Maneo A, Landoni F, Cormio G, Colombo A, Mangioni C. Radical hysterectomy for recurrent or persistent cervical cancer following radiation therapy. Int J Gynecol Cancer. 1999 Jul;9(4):295-301. |
12) | Patel NR, Rollison DE, Barnholtz-Sloan J, Mackinnon J, Green L, Giuliano AR. Racial and ethnic disparities in the incidence of invasive cervical cancer in Florida. Cancer. 2009 Sep 1;115(17):3991-4000. |